Agronomics Ltd. logo

Agronomics Ltd. (AGNMF)

Market Closed
7 Aug, 20:00
OTC PINK OTC PINK
$
0. 08
0
0%
$
103.02M Market Cap
- P/E Ratio
- Div Yield
5,105 Volume
- Eps
$ 0.08
Previous Close
Add Transaction
Day Range
0.08 0.08
Year Range
0.06 0.14
Want to track AGNMF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AGNMF closed Friday higher at $0.08, an increase of 0% from Thursday's close, completing a monthly decrease of -31.6823% or -$0.04. Over the past 12 months, AGNMF stock lost -5.8824%.
AGNMF is not paying dividends to its shareholders.
The last earnings report, released on Mar 12, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on LSE (GBX).

AGNMF Chart

Agronomics Ltd. (AGNMF) FAQ

What is the stock price today?

The current price is $0.08.

On which exchange is it traded?

Agronomics Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is AGNMF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 103.02M.

Has Agronomics Ltd. ever had a stock split?

No, there has never been a stock split.

Agronomics Ltd. Profile

Capital Markets Industry
Financials Sector
James Mellon CEO
OTC PINK Exchange
IM00B6QH1J21 ISIN
IM Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Agronomics Limited, founded on May 3, 2011, and based in Ramsey, Isle of Man, is a distinguished private equity and venture capital firm focusing on investments in emerging growth companies. Specializing in seed/startup, early venture, and growth capital investments, Agronomics Limited has established itself in the investment world by preferring to direct its funds towards the alternative proteins sector, particularly those involved in cellular agriculture, cultivated meat, and modern foods and materials technologies. Furthermore, the firm has broadened its investment horizon to include the biopharma sector, aiming to create a diversified portfolio across biotechnology and biopharmaceutical companies. Agronomics Limited's investment strategy is notable for its commitment to investing in both quoted and unquoted companies, making minority investments, and the prudent use of its balance sheet capital for investment purposes. Additionally, the company has shown flexibility in its investment approaches, such as considering investments in biopharma sector debt up to a certain limit and exploring various investment instruments to maximize returns and impact in the targeted sectors.

Products and Services

  • Investment in Alternative Proteins: Agronomics Limited is keenly focused on investing in companies engaged in cellular agriculture and cultivated meat. The firm targets businesses developing the next generation of food products, aiming to revolutionize the food industry by making it more sustainable and ethical.
  • Investment in Modern Foods and Materials Technologies: The firm looks to support nascent industries that are pioneering new materials and foods through innovative technologies. This includes a broad spectrum of companies, from those developing lab-grown materials to eco-friendly food alternatives, indicating a broad interest in sustainable and ethical innovation.
  • Investment in Biopharma Sector: Agronomics expands its investment portfolio by focusing on the biopharma sector. This encompasses investments in biotechnology and biopharmaceutical companies developing groundbreaking medical treatments and health-related technologies. The firm's strategy includes making minority investments and possibly investing in biopharma sector debt, reflecting a comprehensive approach to fostering innovation in healthcare.
  • Investments in Collective Investment Schemes and LEAPS: Agronomics Limited may also invest in shares of collective investment schemes that have exposure to the biopharma sector, which allows diversification of investment risks and returns. Furthermore, the firm considers long-term equity anticipation securities (LEAPS), particularly those based on biopharma sector securities or indices, as a way to hedge or leverage its investments in the biopharma sector over the long term.

Contact Information

Address: Viking House
Phone: 44 1624 777562